MYT1L-associated neurodevelopmental disorder: description of 40 new cases and literature review of clinical and molecular aspects

2021 ◽  
Author(s):  
Juliette Coursimault ◽  
Anne-Marie Guerrot ◽  
Michelle M. Morrow ◽  
Catherine Schramm ◽  
Francisca Millan Zamora ◽  
...  
2018 ◽  
Vol 61 (3) ◽  
pp. 157-160 ◽  
Author(s):  
Krzysztof Szczałuba ◽  
Anna Biernacka ◽  
Krystyna Szymańska ◽  
Piotr Gasperowicz ◽  
Joanna Kosińska ◽  
...  

2021 ◽  
Author(s):  
Hai Duc Nguyen ◽  
Hojin Oh ◽  
Byung Pal Yu ◽  
Ngoc Minh Hong Hoang ◽  
Won Hee Jo ◽  
...  

Background: Converging evidence indicates prolactin (PRL) and diabetes play an important role in the pathophysiology of cognitive impairment. However, little is known about the mechanisms responsible for the effects of PRL and diabetes on cognitive impairment. Summary: We summarize and review the available literature and current knowledge of the association between PRL and diabetes on aspects of cognitive impairment. Key Messages: The PI3K/AKT pathway is central to the molecular mechanisms underlying how PRL and diabetes interact in cognitive impairment. Further work is needed to identify the interaction between PRL and diabetes, especially in the molecular aspects of cognitive impairment, which can suggest novel strategies for cognitive dysfunction treatment.


Author(s):  
Giulia Pascolini ◽  
Federica Gaudioso ◽  
Chiara Passarelli ◽  
Antonio Novelli ◽  
Niccolò Di Giosaffatte ◽  
...  

Author(s):  
Emanuela Santini ◽  
Anders Borgkvist

Autism spectrum disorder (ASD) is a neurodevelopmental disorder with complex genetic architecture and heterogeneous symptomatology. Increasing evidence indicates that dysregulated brain protein synthesis is a common pathogenic pathway involved in ASD. Understanding how genetic variants converge on a common molecular signaling pathway in neurons and brain circuits, resulting in ASD-relevant synaptic and behavioral phenotypes, is of great interest in the autism research community. This article focuses on ASD-risk genes and the molecular aspects leading to dysregulated protein synthesis.


2016 ◽  
Vol 2 ◽  
pp. 139-142
Author(s):  
Michał Rogowski-Tylman ◽  
Joanna Narbutt ◽  
Anna Woźniacka ◽  
Aleksandra Lesiak

Genes ◽  
2021 ◽  
Vol 12 (5) ◽  
pp. 738
Author(s):  
Jair Tenorio-Castaño ◽  
Beatriz Morte ◽  
Julián Nevado ◽  
Víctor Martinez-Glez ◽  
Fernando Santos-Simarro ◽  
...  

Schuurs–Hoeijmakers syndrome (SHMS) or PACS1 Neurodevelopmental disorder is a rare disorder characterized by intellectual disability, abnormal craniofacial features and congenital malformations. SHMS is an autosomal dominant hereditary disease caused by pathogenic variants in the PACS1 gene. PACS1 is a trans-Golgi-membrane traffic regulator that directs protein cargo and several viral envelope proteins. It is upregulated during human embryonic brain development and has low expression after birth. So far, only 54 patients with SHMS have been reported. In this work, we report on seven new identified SHMS individuals with the classical c.607C > T: p.Arg206Trp PACS1 pathogenic variant and review clinical and molecular aspects of all the patients reported in the literature, providing a summary of clinical findings grouped as very frequent (≥75% of patients), frequent (50–74%), infrequent (26–49%) and rare (less than ≤25%).


2020 ◽  
Author(s):  
Soo Yeon Kim ◽  
YoungKyu Shim ◽  
Young Joon Ko ◽  
Soojin Park ◽  
Se Song Jang ◽  
...  

Abstract Background GNAO1 encephalopathy is a rare neurodevelopmental disorder characterized by distinct movement presentations and early onset epileptic encephalopathy. Here, we report the in-depth phenotyping of genetically confirmed patients with GNAO1 encephalopathy, focusing on movement presentations. Results Six patients who participated in Korean Undiagnosed Disease Program were diagnosed to have pathogenic or likely pathogenic variants in GNAO1 using whole exome sequencing. All medical records and personal video clips were analyzed with a literature review. Three of the 6 patients were male. Mean follow-up duration was 39 months (range, 7–78 months) and age at last examination was 8.0 years (range, 3.3–16.9 years). Initial complaints were hypotonia or developmental delay in 5 and right-hand clumsiness in 1 patient, which were noticed at 20 months of age on average (range, 0–75 months). All patients showed global developmental delay and 4 had severely retarded development. Five patients (5/6, 83.3%) had many different movement symptoms with various onset and progression. The symptoms included stereotyped hands movement, non-epileptic myoclonus, dyskinesia, dystonia and choreoathetosis. Whole exome sequencing identified 6 different variants in GNAO1. Three were novel de novo variants and atypical presentation was noted in a patient. One variant turned out to be inherited from patient’s mother who had mosaic variant. Distinct phenotypes in patients with variant p.Glu246Lys and p.Arg209His were elucidated by in-depth phenotyping and literature review. Conclusions We reported 6 patients with GNAO1 encephalopathy showing an extremely diverse clinical spectrum on video. Some characteristic movement features identified by careful inspection may also provide important diagnostic insight and practice guidelines.


Sign in / Sign up

Export Citation Format

Share Document